The Institute of Ophthalmology, Moorfields Eye Hospital, City Road, London, EC1V 2PD, UK.
Eye (Lond). 2020 Feb;34(2):241-245. doi: 10.1038/s41433-019-0699-1. Epub 2019 Nov 27.
Proliferative vitreoretinopathy (PVR) remains a significant challenge for vitreoretinal surgeons. Its incidence, as a complication of retinal detachment, does not appear to have altered despite improvement in surgical techniques. Extensive laboratory research has been undertaken to investigate the pathogenesis of PVR and the use of adjunctive mediations to modify the disease process. To date these studies have not resulted in improved clinical management of PVR. Previous concepts of the pathogenesis of PVR, focussing on a central role for RPE cells, may be flawed and could potentially have contributed to the lack of clinical advances. Revised clinical classifications and novel approaches to adjunctive treatment may in the future result in improved surgical outcomes.
增生性玻璃体视网膜病变(PVR)仍然是玻璃体视网膜外科医生面临的重大挑战。尽管手术技术有所改进,但作为视网膜脱离的并发症,其发病率似乎并未改变。已经进行了广泛的实验室研究来研究 PVR 的发病机制和使用辅助药物来改变疾病过程。迄今为止,这些研究并未改善 PVR 的临床管理。以前关于 PVR 发病机制的概念,侧重于 RPE 细胞的核心作用,可能存在缺陷,并可能导致临床进展缺乏。修订后的临床分类和辅助治疗的新方法可能会在未来带来更好的手术效果。